Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series

@article{Basnayake2013UseOR,
  title={Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series},
  author={Chaminda Basnayake and Kathy Cash and Peter C. Blumbergs and Vidya S. Limaye},
  journal={Clinical Rheumatology},
  year={2013},
  volume={34},
  pages={371-377}
}
The purpose of the study was to undertake an audit of the use of rituximab in refractory idiopathic inflammatory myositis (IIM). Patients with biopsy-proven refractory IIM treated with rituximab, attending the rheumatology clinic at the Royal Adelaide Hospital were identified by searching the electronic database of patient records from 2007 to March 2013. Seven cases (five women, two men), age range 31 to 68 years with histologically confirmed IIM, were identified. All patients had received… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Myositis autoantibodies

  • L Casciola-Rosena, AL Mammen
  • Curr Opin Rheumatol
  • 2012

Long term safety of patients receiving rituximab in rheumatoid arthritis clinical trials

  • RF Van Vollenhoven, P Emery, CO 3rdBingham, EC Keystone, R Fleischmann, DE Furst
  • J Rheumatol
  • 2010
2 Excerpts

Similar Papers

Loading similar papers…